HEALTH OF WOMAN. 2019.8(144): 16–22; doi 10.15574/HW.2019.144.16
O.V. Gorbunova, N.A. Yermolovich
Shupyk National Medical Academy of Postgraduate Education Ministry of Health of Ukrain, Kiev

Bacterial vaginosis occupies a special place among infectious-inflammatory diseases of the female sexual system. The increase in the frequency of these diseases is due to a number of factors whose effects can be reduced or eliminated altogether. The proportion of bacterial vaginosis among vulvovaginal infections depends on ethnic characteristics, environmental factors, as well as the number of women. Bacterial vaginosis acts as a risk factor for complications during pregnancy, in childbirth and in the postnatal period. Relapses of the disease develop in every second woman regardless of the treatment regimen. Meta-analysis has shown that the development of bacterial vaginosis can be associated with more than 200 species of microorganisms. In women with bacterial vaginosis, there is an increase of 1.5 times the relative risk of infection with human papilloma virus, and therefore the development of cervical neoplasia.

In many countries of the world, the increase in inflammatory diseases is a result of population migration, urbanization, changes in sexual behaviour, deterioration of the environmental situation, etc. It is known that microorganisms in biofilms become practically inaccessible to immune protection factors, so the survival of colonies in biofilms is significantly increased. Standard approaches based on the principles of evidence-based medicine should be used to diagnose and treat bacterial vaginosis. International recommendations for the treatment of bacterial vaginosis include therapy aimed at eliminating the agent, alleviating symptoms of the disease, increasing local and general immunities and normalizing biocinosis. In general, treatment patterns according to the recommendations of different medical societies are similar.

Treatment of asymptomatic forms of bacterial vaginosis in pregnant women reduces the incidence of complications of pregnancy, childbirth and the postpartum period. For the treatment of patients with insufficient motivation, it is desirable to give preference to schemes that have proven their distant anti-clinical effectiveness. Two-stage therapy of bacterial vaginosis using modern local combination antiseptic drug of wide spectrum action Limendа and with mandatory restoration of vaginal microflora with the preparation Вreveluck are effective in treatment of bacterial vaginosis and reduce risk of relapses.

Key words: bacterial vaginosis, Limenda, Вreveluck.

REFERENCES

1. Boiko HB. 2012. Bakterialnyi vahinoz: suchasnyi pohliad na problemu. Ukrainskyi medychnyi chasopys 5 (91); IX/X: 91–93.

2. Radzinskiy VE. 2009. Zhenskaya konsultatsiya: Rukovodstvo. Pod red. Radzinskogo VE. 3-e izd., ispr. i dop. M, GEOTAR Media:472.

3. Livengood CH. 2009. Bacterial vaginosis: an overview for 2009. Rev. Obstet. Gynecol. 2 (1): 28–37.

4. Rogovskaya SI, Lipova EV. 2014. Sheyka matki, vlagalische, vulva. Fiziologiya, patologiya, kolposkopiya, esteticheskaya korrektsiya: rukovodstvo dlya praktikuyuschih vrachey. Pod red. Rogovskoy SI, Lipovoy EV. M, Izdatelstvo zhurnala Status Piaesens: 832.

5. Fethers KA, Fairley CK, Hocking JS, Gurrin LC, Bradshaw CS. 2008. Sexual risk factors and bacterial vaginosis: a systematic review and meta analysis. Clin. Infect. Dis. 47: 1426–35. https://doi.org/10.1086/592974; PMid:18947329

6. Voronin KV, Nahla BS, Chuyko VI i dr. 2012. Bakterialnyi vaginoz beremennyh: etiologicheskaya diagnostika, prognozirovanie i printsipy aktivnoi profilaktiki infektsionnyh i perinatalnyh oslozhneniy. Tavrich. med.-biolog. vestn. 15 (2):40–43.

7. Radzinskiy VE. 2011. Akusherskaya agressiya. M, Mediabyuro Status prezens: 688.

8. Radzinskiy VE, Ordiyants IM. 2012. Dvuhetapnaya terapiya vaginalnyih infektsiy. Rezultaty rossiyskogo mnogotsentrovogo issledovaniya «Sravnitelnaya otsenka razlichnyh shem lecheniya vaginalnyh bakterialnyh infektsiy nespetsificheskoi etiologii (BIOS)». M, Redaktsiya zhurnala StatusPraesens: 16.

9. Modak Т, Arora P, Agnes C, Ray R, Goswami SP, Das NK. 2011, May 28. Diagnosis of bacterial vaginosis in cases of abnormal vaginal discharge: comparison of clinical and microbiological criteria. J. Infect. Dew Ctries 5 (5): 353–360. https://doi.org/10.3855/jidc.1153; PMid:21628811

10. Gillet Е. 2011, Jan. Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: a metaanalysis. BMC Infect. Dis. 11. https://doi.org/10.1186/1471-2334-11-10; PMid:21223574 PMCid:PMC3023697

11. Golianovskyi OV, Mekhedko VV, Budchenko MA. 2017. Suchasni pidkhody do likuvannia bakterialnoho vahinozu ta zmishanyh nespetsyfichnykh vahinitiv. Zdorove zhenshchyny 8 (124): 89–95.

12. Pobedinskiy NM, Aksenova OA, Aksenova MG, Molochkov VA. 2006. Kliniko-bakteriologicheskoe obosnovanie kompleksnogo lecheniya bakterialnogo vaginoza u zhenschin reproduktivnogo vozrasta. Akusherstvo i ginekologiya 6: 24–27.

13. Bradshaw CS. 2006. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J. Infect. Dis. 193:1478. https://doi.org/10.1086/503780; PMid:16652274

14. Rahmatulina MR, Plahova KI. 2012. Bakterialnyiy vaginoz, assotsiirovannyiy s Atopobium vaginae: sovremennyie printsipyi diagnostiki i terapii. Akusherstvo i ginekologiya 3: 88–92.

15. Rudneva OD, Dobretsova TA, Makletsova SA. 2013. Retsidivyi bakvaginoza i laktoflora: ot aktualnoy neodnoznachnosti k prakticheskim resheniyam. Pod red. V.E. Radzinskogo. M, Redaktsiya zhurnala StatusPraesens: 16.

16. Ferris MJ et al. 2004. Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect. Dis. 4:5–13. https://doi.org/10.1186/1471-2334-4-5; PMid:15018635 PMCid:PMC362875

17. Bradshaw CS, Tabrizi SN, Fairley CK et al. 2006. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J. Infect. Dis. 194 (6): 828–836.

18. Safronova MM, Grenkova YuM. 2009. Narushenie vlagalischnogo mikrobiotsenoza: sovremennyie metody korrektsii. Klin. dermatol. venerol. 6: 23–25.

19. Chebotar IV. 2012. Mikrobnyie respubliki i antimikrobnaya tiraniya. StatusPraesens 4(10): 21–24.

20. Patterson JL. 2010. Analysis of adherensce, biofilm formation and cytotoxicity suggests a greater virulence potential of Gardnerella vaginal relative to other bacterial vaginosis associated anaerobes. Microbiology 156 (Pt. 2): 392–399. https://doi.org/10.1099/mic.0.034280-0; PMid:19910411 PMCid:PMC2890091

21. Reid G, Burton J. 2002.  Use of Lactobacillus to prevent infection by pathogenic bacteria. Microbes Infect. 4 (3): 319–324. https://doi.org/10.1016/S1286-4579(02)01544-7

22. Baloğlu E, Ozyazici M, Baloğlu A, Ova L. 2003. A randomized controlled trial of a new ovule formulation of ornidazole for the treatment of bacterial vaginosis. J. Clin. Pharm. Ther.  28 (2): 131–136. https://doi.org/10.1046/j.1365-2710.2003.00472.x; PMid:12713610

23. Leitich H, Bodner-Adler В, Brunbaure M, Kaider A, Egarter C, Husselin P. 2003. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am. J. Obstet. Gynecol. 189: 139–147. https://doi.org/10.1067/mob.2003.339; PMid:12861153

24. Thulkar J, Kriplani A, Agarwal N. 2012. A comparative study of oral single dose of metronidazole, tinidazole, secnidazole and ornidazole in bacterial vaginosis. Indian J. Pharmacol. 44 (2): 243–245. https://doi.org/10.4103/0253-7613.93859; PMid:22529484 PMCid:PMC3326921

25. De Backer E, Dubreuil L, Brauman M et al. 2010. In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved in bacterial vaginosis. Clin. Microbiol. Infect. 16 (5): 470–472. https://doi.org/10.1111/j.1469-0691.2009.02852.x; PMid:19548924

26. Gomberg MA, Plahova K. 2005. Infektsii vlagalischa: vzglyad venerologa Terapiya trihomoniaza i bakterialnogo vaginoza: problemy i puti resheniya. Consilium Medicum 03:210–214.

27. Petricevic L. 2008. The role of Lactobacillus casei rhamnosus Lcr35 in restoring the normal vaginal flora after antibiotic treatment of bacterial vaginosis. BJOG. 115; 11: 1369–1374. https://doi.org/10.1111/j.1471-0528.2008.01882.x; PMid:18823487

28. Reid G, Burton J. 2002.  Use of Lactobacillus to prevent infection by pathogenic bacteria. Microbes Infect. 4 (3): 319–324. https://doi.org/10.1016/S1286-4579(02)01544-7

9. Instruktsiia dlia medychnoho zastosuvannia likarskoho zasobu Limenda (Limenda).

30. Instruktsiia dlia medychnoho zastosuvannia likarskoho zasobu Brevelak (Vreveluck).

31. Sobel JD, Ferris D, Schwebke J et al. 2006. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol. 194:1283–9. https://doi.org/10.1016/j.ajog.2005.11.041; PMid:16647911